Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids

PHASE4UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

March 31, 2021

Conditions
Non-infectious Anterior Uveitis
Interventions
DEVICE

Dextenza Dexamethasone Implant

The area of the punctum is first anesthetized with eye drops. A localized injection of lidocaine in perform once the surface of the punctum is numbed with the eyedrop. After 5-10 minutes, the corner of the eyelid and the region of the punctum will be fully anesthetic. The upper and lower punctum are then dilated with a punctum dilator to facilitate the insertion of the DEXTENZA medication. The DEXTENZA medication is then inserted using smooth forceps into the dilated opening of the upper and lower punctum. Once the DEXTENZA is inserted into the both the upper and lower punctum, the procedure is down. No repeated insertion of the DEXTENZA is required for the study.

DRUG

Topical Prednisolone Acetate 1%

"Topical corticosteroid (Pred Forte, prednisolone acetate 1%) standard of care tapered treatment regimen of~8x/day week 1 4x/day week 2 2x/day week 3~1x/day week 4~Visit schedule: Baseline, Day 3, Day 7, Day 14, and Day 30"

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ocular Therapeutix

UNKNOWN

lead

New England Retina Associates

OTHER

NCT04426734 - Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids | Biotech Hunter | Biotech Hunter